[1] MOHAN S, GU S, PARIKH A, et al. Prevalence of hyponatremia and association with mortality: results from NHANES[J]. Am J Med, 2013,126(12):1127-1137.
[2] SICA D A. Hyponatremia and heart failure—pathophysiology and implications[J]. Congest Heart Fail, 2005,11(5):274-277.
[3] JAO G T, CHIONG J R. Hyponatremia in acute decompensated heart failure: mechanisms, prognosis, and treatment options[J]. Clin Cardiol, 2010,33(11):666-671.
[4] 中国医师协会心力衰竭专业委员会, 国家心血管病专家委员会心力衰竭专业委员会, 中华心力衰竭和心肌病杂志编辑委员会, 等. 中国心力衰竭患者离子管理专家共识[J]. 中华心力衰竭和心肌病杂志, 2020, 4(1):16-31.
[5] DE VECCHIS R, ESPOSITO C, ARIANO C, et al. Hypertonic saline plus i.v. furosemide improve renal safety profile and clinical outcomes in acute decompensated heart failure[J]. Herz, 2015,40(3):423-435.
[6] GHALI J K, HAMAD B, YASOTHAN U, et al. Tolvaptan[J]. Drug Discovery, 2009,8(8):611-612.
[7] HAUPTMAN P J, BURNETT J, GHEORGHIADE M, et al. Clinical course of patients with hyponatremia anddecompensated systolic heart failure and the effect ofvasopressin receptor antagonism with tolvaptan[J]. J Cardiac Fail, 2013,19(6):390-397.
[8] 老年患者低钠血症的诊治中国专家建议写作组. 老年患者低钠血症的诊治中国专家建议[J]. 中华老年医学杂志, 2016,35(8):795-804.
[9] WATANABE K, DOHI K, SUGIMOTO T, et al. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure[J]. J Cardiol, 2012,60(6):462-469.
[10] LUO X, JIN Q, WU Y. Tolvaptan add-on therapy in patients with acute heart failure: a systematic review and meta-analysis[J]. Pharmacol Res Perspect, 2020,8(3):e00614.
[11] KINUGAWA K, SATO N, INOMATA T, et al. Efficacy and safety of tolvaptan in heart failure patients with volume overload[J]. Circ J, 2014,78(4):844-852. |
